Ultromics has been working with the NHS since 2017 to train, pilot and validate EchoGo, across 30 NHS sites in one of the largest echo studies of its kind.
In 2020, Ultromics received a £2.7 million grant from NHSX to fast-track EchoGo into Trusts and make it commercially available. The goal is to introduce doctors to the benefits of cloud and ease time and resource burden, whilst ensuring accuracy and eliminating variability, one of the main issues with echo diagnosis.
"Myocardial strain is a highly valuable measure used to quantifying left ventricular (LV) function. It is more sensitive than Left Ventricular Ejection Fraction (LVEF) and represents an important yet often overlooked measure. EchoGo provides our physicians with AI based strain analysis on the more than a thousand echocardiography exams we perform each month, acquired at multiple locations throughout greater Long island.
Ultromics has been an excellent partner in delivering cutting edge technology and services to us. Their products and expertise are best in class, allowing us to perform accurate wall motion analysis on all our patients"